Synthesis of trans-caffeate analogues and their bioactivities against HIV-1 integrase and cancer cell lines

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 24, 2008, Pages 6553-6557

  Xia, Chun nian ^a   Li, Hai bo ^b   liu, Feng ^a   Hu, Wei xiao ^a  

^a ZHEJIANG UNIVERSITY OF TECHNOLOGY   (China)

^b Nantong Center for Disease Control and Prevention   (China)

Author keywords

Antitumor; Caffeate analogues; HIV 1 integrase

Indexed keywords

5 NITROCAFFEIC ACID; 5 NITROCAFFEIC ACID PHENETHYL ESTER; BORNYL 2 NITROCAFFEATE; BORNYL CAFFEATE; CAFFEIC ACID DERIVATIVE; CISPLATIN; INTEGRASE INHIBITOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; PRODUCT RECOVERY; STOMACH CANCER;

ANTINEOPLASTIC AGENTS; BINDING SITES; BIOTIN; CAFFEIC ACIDS; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, CHEMICAL; STRUCTURE-ACTIVITY RELATIONSHIP;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 56249087269     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.10.046     Document Type: Article

References (25)

1. Greenaway W., and Whatley F.R. J. Chromatogr. 54 (1991) 3113
2. Son S., and Lewis B.A. J. Agric. Food Chem. 50 (2002) 486
3. Sahinler N., and Kaftanoglu O. Nat. Prod. Res. 19 2 (2005) 183
4. Kujumgiev A., Bankova V., Ignatova A., and Popov S. Pharmazie 48 10 (1993) 785
5. Fesen M.R., Kohn K.W., Leteurtre F., and Pommier Y. Proc. Natl. Acad. Sci. U.S.A. 90 6 (1993) 2399
6. Orban Z., Mitsiades N., Burke Jr. T.R., Tsokos M., and Chrousos G.P.J. Neuroimmunology 7 2 (2000) 99
7. Natarajan K., Singh S., Burke Jr. T.R., Grunberger D., and Aggarwal B.B. Proc. Natl. Acad. Sci. U.S.A. 93 17 (1996) 9090
8. Burke Jr. T.R., Fesen M.R., and Mazumde A. J. Med. Chem. 38 (1995) 4171
9. Fesen M.R., Pommier Y., Leteurtre F., Hirogushi S., Yung J., and Kohn K. Biochem. Pharmcol. 48 (1994) 595
10. Nagaoka T., Banskota A.H., Tezuka Y., Saiki I., and Kadota S. Bioorg. Med. Chem. Lett. 10 (2002) 3351
11. Chen W.K., Tsai C.F., Liao P.H., Kuo S.C., and Lee Y.Z. Chin. Pharm. J. 51 4 (1999) 271
12. Huang M.T., Ma W., Yen P., Xie J.G., Han J., Frenkel K., Grunberger D., and Conney A.H. Carcinogenesis 17 4 (1996) 761
13. Chen J.H., Shao M.S., Huang M.T., Chin C.K., and Ho C.T. Cancer Lett. 108 (1996) 211
14. Chen Y.J., Shiao M.S., Hsu M.L., Tsai T.H., and Wang S.T. J. Agric. Food Chem. 49 (2001) 5615
15. Mahmoud N.N., Carothers A.M., Grunberger D., Bilinshi R.T., Churchill M.R., Martucci C., Newmark H.L., and Bertagnolli M.M. Carcinogenesis 21 (2000) 921
16. Grunberger D., Banerjee R., Eisinger K., Oltz E.M., Efros L., Caldwell M., Estevez V., and Nakanishi K. Experientia 44 3 (1988) 230
17. Xia C.N., and Hu W.X. J. Chem. Res. Synop. 9 (2006) 586
18. Bankova V.S. J. Nat. Prod. 53 4 (1990) 821
19. 2) = 0.124 (all data). Full crystallographic details of III-26 have been deposited at the Cambridge Crystallographic Data Center and allocated the deposition number CCDC 673003.
20. Perea R.A., Fernhndez-Alvarez E., Nieto O., and Piedrdita F.J. J. Med. Chem. 35 (1992) 4584
21. Appendino G., Daddario N., Minassi A., Moriello A.S., Petrocellis L.D., and Marzo V.D. J. Med. Chem. 48 (2005) 4663
22. Thi B.T.L., Iiyama K., and Stone B.A. Phytochemistry 41 (1996) 1507
23. Vallejos G., Fierro A., Rezende M.C., Sepulveda-Boza S., and Reyes-Parada M. Bioorg. Med. Chem. 13 (2005) 4450
24. +), 180 (100), 163 (61), 134 (34), 105 (50), 104 (66), 89 (53), 77 (49), 51 (33).
25. Chan W.S., Wen P.C., and Chiang H.C. Anticancer Res. 15 (1995) 703